Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA9 | Q16790 | 8/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312975 | 0.87 | PTGS2 (0.46) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL348164 | 0.78 | CA2 (0.44) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL7216716 | 0.78 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL5315712 | 0.76 | PTGS2 (0.52) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL27508390 | 0.74 | PTGS2 (0.42) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL3690377 | 0.71 | PTGS2 (0.41) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL5309137 | 0.70 | PTGS2 (0.46) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL2465761 | 0.69 | PTGS2 (0.53) | CHRNA7PTGS2PTGS1CYP2D6 | |
| SCHEMBL2465669 | 0.69 | PTGS2 (0.62) | CA12CA1CA2CA9CHRNA7 | |
| SCHEMBL5314020 | 0.67 | CHRNA7 (0.60) | CA12CA1CA2CA9CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | claimed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-7745481-B2 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| US-6887893-B1 | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED | 2005-01-06 | — | — | US | disclosed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | CA12 806/4885CA1 981/4885CA2 520/4885 |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | CA12 806/4885CA1 981/4885CA2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.